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Cost-effectiveness models often require the consideration of a sequence of treat-
ments. This enables the downstream implications of a treatment to be captured, and 
alternative sequences to be compared. However, when many treatments are available, 
the number of feasible sequences can be large. Also, if the objective is to maximise net 
benefit for a given ICER threshold, then a comparative analysis to identify the optimal 
sequence may not be possible. This is further compounded when using individual 
patient simulation (IPS), because of the increased computational burden compared 
with cohort approaches. The aim of this study was to undertake a systematic review 
of optimisation methods that are applicable to a treatment sequencing IPS model. 
28 key papers were identified across a range of academic subjects. Metaheuristics 
including simulated annealing, tabu search and genetic algorithms have been 
applied to simulation-optimisation problems and a bespoke review framework was 
applied to determine their appropriateness. Based on the review, a framework for 
the economic evaluation of treatment sequences was developed. The framework 
considers the requirements of a cost-effectiveness model to efficiently evaluate 
sequences, the application of the reviewed metaheuristics to determine the optimal 
sequence, and the consideration of these results within a decision-making context. 
This will be applied to a case study in rheumatoid arthritis. Alternative metaheuris-
tic algorithms will be applied in an attempt to estimate a (near) optimal treatment 
sequence. Preliminary results of these experiments will be available in time for the 
November 2014 ISPOR conference. If these methods prove successful and feasible, 
then the framework may have potential applicability to sequencing models in many 
diseases. Whether there is the capability for it to be applicable within the current 
process for decision-making organisations such as NICE remains an open question, 
however, identifying an optimal sequence in a decision problem is of interest to 
decision makers.
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Pharmerit International, Bethesda, MD, USA
BAckground: Common indirect treatment comparison (ITC) methodology in over-
active bladder involves combining absolute reduction in urge urinary incontinence 
(UUI) episodes at study endpoint (e.g., week 12) to estimate the overall treatment 
effect. Trials with differing endpoints must assume equivalence to be included in 
the network. Further, analyses of endpoint data are not sufficient to predict efficacy 
at intermediate time points (e.g. 4 or 6 weeks). We developed and tested an alternate 
methodology to utilize available intermediate time points into an ITC of published 
studies of fesoterodine and tolterodine. Methodology: Study-level mean UUI 
reduction over time can be represented as the percent reduction from baseline, 
which can be modeled as a monotonically-increasing function with a theoretical 
maximum of 100%. This function is expressed with two parameters: %red = bi*time/ 
(ci + time), where bi is the maximum possible reduction for treatment i, and ci is the 
time required to reach half the maximum reduction. The inverse %red is a linear 
function of 1/time that can be used within a Bayesian ITC framework to generate 
a placebo-adjusted indirect comparison of efficacy. conclusions: The endpoint 
results obtained from the alternate methodology were comparable to those obtained 
from an endpoint ITC. This novel methodology has the additional advantage of 
utilizing all available time point data within a single analysis, which can then be 
used to generate efficacy estimates at intermediate time points, which may be 
utilized within economic models. Limitations include unavailability of uncertainty 
estimates of the %red variable and difficulty of estimating combinations of param-
eters within functional constraints. Finally, our alternate methodology may be used 
for any longitudinal data exhibiting a monotonic increase or decrease and may be 
expanded to include a network with multiple treatments.
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bayesIaN Models foR cost-effectIveNess aNalysIs IN the PReseNce of 
stRuctuRal ZeRo costs
Baio G.
University College London, London, UK
Bayesian modelling for cost-effectiveness data has received much attention in 
both the health economics and the statistical literature, in recent years. Cost-
effectiveness data are characterised by a relatively complex structure of relation-
ships linking a suitable measure of clinical benefit (\eg QALYs) and the associated 
costs. Simplifying assumptions, such as (bivariate) normality of the underlying dis-
tributions are usually not granted, particularly for the cost variable, which is charac-
terised by markedly skewed distributions. In addition, individual-level datasets are 
often characterised by the presence of structural zeros in the cost variable. Hurdle 
models can be used to account for the presence of excess zeros in a distribution and 
have been applied in the context of cost data. We extend their application to cost-
effectiveness data, defining a full Bayesian specification which consists of a pattern 
model for the individual probability of null costs, a marginal model for the costs 
and a conditional model for the measure of effectiveness (given the observed costs). 
The model is presented using a working example to describe its main features. In 
addition, we present a R package (BCEs0) that directly implements this framework 
and can be used to run a full Bayesian cost-effectiveness analysis of individual data 
in the presence of structural zero costs for some subjects.
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Health Information and Quality Authority, Dublin, Ireland
Prioritisation of assessment topics is an essential activity within HTA. Failure to 
successfully identify technologies that are likely to have the greatest impact on 
the health system carries an opportunity cost that is measured in poorer decision 
tred care and integration of the patient perspective in health care policy decisions. 
A major challenge for the integration of evidence on patient preference is that 
research on patient preferences is performed by various disciplines (e.g. psychology 
and economics) that do not share a common language. It has been recommended to 
perform conceptual and taxonomic work on the definition and conceptualisation 
of ‘preference’ and related terms. The aim of this study was to develop a taxonomy 
of preference-related terms. The taxonomy was developed in three steps: 1) the 
identification of preference-related terms; 2) providing all identified terms with 
a definition from the dictionary; and 3) the identification of dominant theories 
or models from (health) economics and psychology that deal with the reference-
related terms. The proposed taxonomy consists of several building blocks that hold 
all identified preference-related terms and demonstrate the relation between terms. 
The building blocks are centred around a factual event. Ex ante to this factual event 
lies building block 1, “decision making” holding terms like “choice” and “decision”. 
Ex post lie building block 2 “evaluation process” and building block 3 “outcome of 
evaluation process”. Building block 3 holds terms like “utility”, “quality of life” and 
“satisfaction”. Building blocks 1-3 are influenced by building block 4 “the value 
system”. This value system is divided in cognition, affect and conation and holds 
terms like “beliefs”, “expectation”, “attitudes”, “desires” and “intention”. In this tax-
onomy, preferences can be considered as a part of the value system. The proposed 
taxonomy is a first step towards conceptual clarity to facilitate the integration of 
research evidence in health care policy decisions.
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WheN It May Not be NecessaRy to Model oveRall suRvIval foR 
ecoNoMIc evaluatIoNs of aNtI-caNceR dRugs
Hoyle M.1, Hamilton W.1, Rudin C.2
1University of Exeter, Exeter, UK, 2Royal Devon & Exeter Hospital, Exeter, UK
Overall survival (OS) is traditionally modelled in economic evaluations of anti-cancer 
drugs. However, OS is commonly associated with problems such as immaturity of the 
data, or confounding due to treatment switching or use of inappropriate treatments 
after progression. Fortunately, analysis of historical trials reveals that there is good 
evidence across a range of cancers that the mean time in post-progression survival 
(PPS) is equal between treatment arms, i.e. Δ PPS = 0. Therefore, we recommend that 
the default position is to assume equal mean times post-progression. If there is no 
a priori biological reason to suppose that the PPS times are likely to differ between 
treatments (e.g. due to differences in cross-resistance or long term toxicities between 
treatments), our recommendation is that it should be assumed that the mean time in 
progressive disease is equal between treatment arms if any of the following apply: OS 
is very immature; treatments post-progression are substantially imbalanced between 
treatment arms; in particular, treatment switching has occurred at progression; treat-
ments post-progression are different to those routinely given in clinical practice; only 
single arm trials are available. If none of the above apply, or if there are a priorireasons 
to suggest that Δ PPS differs from 0, then the recommendation is to model OS and PFS 
in the traditional way. For chronic cancers, it is recommended that analyses should 
either assume equal times post initial treatment or equal time post progression. The 
assumption that Δ PPS = 0 substantially simplifies the economic analysis because 
cost-effectiveness becomes insensitive to OS. The methodology has been endorsed 
twice by NICE appraisal committees in assessments of drugs for chronic myeloid 
leukaemia. The cost-effectiveness of several drugs recently assessed by NICE are 
re-calculated using the methods proposed. Next, we give simplified formulae for the 
maximum drug price acceptable for reimbursement under the methodology.
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feasIbIlIty of coNductINg RetRosPectIve studIes usINg hashtags 
aNd socIal MedIa data fRoM facebook aNd tWItteR
Volovyk A.1, Topachevskyi O.2
1Hashtago, Kiev, Ukraine, 2Digital Health Outcomes, Brussels, Belgium
Various online services such as Socialbakers, Keyhole, Gnip offer tools to analyze, 
fetch and collect data from social media. This data is often presented in a form 
of interactive web based dashboards, displaying various trends: number of posts, 
mentions, shares, likes over time. Facebook and Twitter have an API to access data 
on social media profiles of real people. Users profiles usually have data on age, 
sex, employment and relationships status, specific group membership, etc. We 
conducted a simple feasibility study using Facebook API in diabetes area using 
profiles of people posting hashtags as a primary source of data. We then expanded 
the sample by adding people who liked, shared and reposted messages containing 
diabetes relaed hashtags #Diabetes, #dedoc, #ourD. We applied exclusion criteria 
to derive a sample consisting of patients only, hence targeting specific group of 
people. Our assumption was that people who interact with posts containing spe-
cific hashtag have diabetes. We used descriptive statistics to characterize obtained 
sample (n= 17296) by calculating mean age, age distribution histogram, proportion 
of males and females and other descriptive metrics. We also calculated conditional 
probabilities of being in multiple disease area Facebook groups such as obesity 
groups or groups of people with increased risk of cardiovascular disease. Future 
area of research will be concentrated on aspects of in-degree centrality in net-
work of diabetic people, hypothesis testing between two different groups, analyses 
of changes in positive/negative posting trends following drug launch, locating 
agents and influencers in the network and conducting prospective studies in 
social media using hashtags. Social Media data can be a valuable addition to a 
real life post launch data. Evidence on changes in positive/negative postings can 
be used as an additional piece of information in Phase IV studies or risk-sharing 
agreements.
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foR chRoNIc coNdItIoNs
Tosh J., Stevenson M., Strong M., Akehurst R.
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There is increasing scrutiny of pharmaceuticals on their value proposition as well as 
a growing demand for evidence on real world effectiveness once they are commer-
cially available. There are many challenges in producing valid and reliable estimates 
of real world effectiveness. A major challenge is assessing a product’s effectiveness 
relative to why patients may respond differently to a treatment (i.e., identifying 
groups of patients exhibiting “Heterogeneity of Treatment Effect” (HTE) using sub-
group identification methods). Assessing HTE is critical to understanding differ-
ences that may exist between the efficacy observed in randomized clinical trials 
and a product’s real world effectiveness. Understanding causes for HTE is required 
for correct attribution of any observed difference between efficacy and effectiveness 
to the product versus other sources (e.g., patient behavior); Not recognizing and 
accounting for HTE will confound assessment of a product’s performance, which 
ultimately affects its acceptance and use by payers, physicians, and patients. Failure 
to define and incorporate subgroups is a frequent criticism of systematic evidence 
reviews and comparative effectiveness research reports. However, the analytical 
methods for finding factors that define subgroups that explain HTE are challenging 
due to many known statistical issues (e.g., limited statistical power, multiplicity 
adjustments) Real world data exacerbates the analytical challenges due in part to 
biases (e.g., selection bias) and issues (e.g., data quality) inherent in the data. We 
will describe the data and bias challenges that create these analytical complexi-
ties for detecting the cause and magnitude of HTE when using real world data. We 
will present results from a simulation experiment that compared and validated 
several subgroup methods developed to address these data and analytical issues. 
We simulated 22 permutations of subgroups with known identification criteria and 
treatment effects to determine the performance of the methods.
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IMPacts of ePRo data collectIoN Mode selectIoN oN PatIeNt 
INclusIoN
Holzbaur E., Ross J., Wade M., Rothrock T.
Almac Clinical Technologies, Souderton, PA, USA
oBjectives: The Electronic Patient Reported Outcome (ePRO) data collection 
mode selected for trials is often based on efforts to minimize timelines, budg-
ets, and patient burden. However, are sponsors inadvertently introducing bias 
into trial results in this selection process? This conceptual paper reviews com-
mon ePRO modes and explores patient groups that may be excluded. Methods: 
Common modes for ePRO data collection are reviewed. An assessment of potential 
patient groups that may be excluded is performed based on ePRO mode. results: 
Common ePRO modes include telephone, web, and handheld device. As sponsors 
look to reduce costs, improve data quality, and reduce patient burden, industry has 
continued its shift towards patients using their own telephone, computer, tablet, 
or smartphone and away from sponsors provisioning these devices to patients. 
Choice of patient-provisioned device: Patients from certain geographic areas may 
be excluded where internet connections and cellular/mobile telephone reception 
is limited. Requiring patients to use their personal web/mobile device may exclude 
patient groups with certain economic, cultural, or demographic characteristics 
who live in rural or underdeveloped areas. Choice of sponsor-provisioned device: 
Logistics issues, i.e. shipment of devices including customs considerations, reli-
ability of data transmission, storage and replacement of devices and cords, train-
ing, etc. conclusions: The objective of clinical trials is to establish treatment 
effectiveness, generalizable to the overall patient population. ePRO mode selection 
may impact inclusion of individuals from certain economic, cultural, demographic, 
and geographic areas. Exclusion of these groups could impact results; therefore, it is 
important to understand the potential bias that can be introduced when selecting 
an ePRO mode. Proper planning should include assessment of patient population 
and inclusion of regions that would render generalizability. ePRO mode selection 
should be based on which method works best for the required regions to optimize 
inclusion, as well as the patient population’s characteristics to minimize burden.
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clINIcal outcoMe assessMeNt (coa) INstRuMeNt scoRINg: the 
valIdIty aNd PRecIsIoN of uNWeIghted suMMaRy scoRes veRsus IRt 
WeIghted scoRes, aNd the added value of IRt staNdaRd eRRoRs
Coon C.D.1, Lenderking W.R.2
1Adelphi Values, Boston, MA, USA, 2Evidera, Lexington, MA, USA
COA development experts in recent years have given thought to the psychomet-
ric evaluation of instruments and their ability to detect meaningful differences 
between patient groups. The scoring of the instruments, however, has received less 
attention, with various approaches sometimes suggested without a clear prefer-
ence or justification. The score is ultimately used for evaluating patient outcomes 
and treatment efficacy and is what requires validation, so this seems like a signifi-
cant omission. We examine the traditionally accepted unweighted summary score 
approach and compare it to the more complex IRT weighted scoring to evaluate if 
the gain in precision justifies the increased scoring complexity. Precision may differ 
depending on whether the score is close to the mean of the population or closer to 
the extreme ends of the distribution. Simulated data are used for this comparison to 
evaluate if the precision of the scores differs depending on the location of the score 
and if the instrument is used for group comparisons versus individual diagnosis. 
Additionally, we recognize that the reliability of a scale is likely to be variable across 
the range of its scores. With that in mind, we consider an approach to comparing 
mean scores between groups that incorporates the standard error of each individual 
IRT score into the model. By using the IRT standard errors, we can adjust for the 
different levels of uncertainty associated with ranges of scores along the scale, 
ultimately providing us greater confidence in the group comparison results.
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evaluatIoN of estIMatoRs of tReatMeNt effect IN obseRvatIoNal 
studIes
Faries D.E.1, Lipkovich I.2, Kadziola Z.3
making, reduced patient benefits and less efficient use of public resources. Within 
individual agencies, prioritisation is also a business function that must balance the 
need to plan for and manage the allocation of resources with the need to provide 
expeditious advice to decision makers and adapt quickly to changing circumstances. 
This research describes a transparent and responsive framework for selecting health 
technologies to assess, minimising the potential for important technologies to be 
missed and providing a useful resource for HTA agencies facing similar issues. 
Topics are identified through a mix of routine horizon scanning, a formally convened 
advisory group consisting of the major decision makers from within the publicly 
funded health system and informal business intelligence gathering. Screening is 
carried out to eliminate technologies that are clearly unsuitable and provision-
ally grade all remaining candidates according to three principal criteria; 1) clinical 
impact (patient population, potential incremental effect and availability of alterna-
tives); 2) economic impact (incremental costs and potential disruptive effect on how 
services are currently organised) and 3) policy impact (link to decision-making and 
factors that make it likely to feature on the national health care agenda). The screen-
ing process feeds into an in-depth expert group discussion, which also considers 
operational issues such as the extent of the advice required to inform the decision, 
data availability and costs associated with the assessment. We also describe a soft-
ware visualisation tool developed to facilitate the prioritisation process, as well as 
measures for quality assurance and ongoing performance evaluation.
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goal attaINMeNt scalINg – a useful INdIvIdualIZed clINIcal 
outcoMe MeasuRe
Jones M., Kharawala S., Langham J., Gandhi P.
Bridge Medical, London, UK
Goal Attainment Scales (GAS) capture outcomes relevant to individual patients and 
provide “real-world” outcome measurement. This abstract will describe the back-
ground to their use, their operationalization, strengths and limitations. Traditional 
outcome measures assess a standardised set of questions regardless of their relevance 
to each patient. GAS overcomes these weaknesses because it is an individualised 
assessment based on achievement of goals which are personal to each patient. 
Despite its widely cited use in academic literature and good psychometric proper-
ties it is rarely used in drug intervention studies. Operationalisation of GAS varies 
but follows these basic steps: 1) The patient’s specific problem areas are assessed and 
goals for each defined; 2) A GAS for each goal is created and an “expected outcome” for 
each agreed; 3) Goal attainment levels are defined for each point on, typically, a 5-point 
scale (expected outcomes are usually scored 0; baseline is often -2, but may be -1 or 
0 depending on potential for deterioration). Each level must be carefully described 
in a way that is relevant, observable, measurable and consistent with study design. 
Published standardised goals are available; and 4) A standardized statistical formula 
provides overall goal attainment. Benefits include: ease of use; relevant goals; no 
redundant items; assessment of multiple domains; provides quantifiable and appli-
cable outcomes across different conditions and severities; potentially more sensitive 
measure than traditional scales. Limitations include: potential bias; appropriate goal 
selection and outcome prediction; observable changes may differ from pre-defined 
outcomes; time consuming; may require independent GAS assessors for blinded tri-
als; may require “control” goals not affected by treatment; statistical issues around 
single overall score. In capturing those outcomes relevant to each individual patient, 
GAS has potential use in supporting product labeling claims and value assessment 
of a medicine by HTA and payers.
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avoIdINg aNd IdeNtIfyINg eRRoRs aNd otheR thReats to the 
cRedIbIlIty of health ecoNoMIc Models
Tappenden P., Chilcott J.
University of Sheffield, Sheffield, UK
Health economic models have become the primary vehicle for undertaking eco-
nomic evaluation and are used in various health care jurisdictions across the world 
to inform decisions about the use of new and existing health technologies. Models 
are required because a single source of evidence, such as a randomised controlled 
trial, is rarely sufficient to provide all relevant information about the expected costs 
and health consequences of all competing decision alternatives. Whilst models are 
used to synthesise all relevant evidence, they also contain assumptions, abstractions 
and simplifications. By their very nature, all models are therefore “wrong.” Whilst 
the presence of imperfect evidence provides the impetus for developing models, it is 
also the reason why we can never fully validate them. As such, the interpretation of 
estimates of the cost-effectiveness of health technologies requires careful judgements 
about the degree of confidence that can be placed in the models from which they 
are drawn. The presence of a single error or inappropriate judgement within a model 
may lead to inappropriate decisions, an inefficient allocation of health care resources 
and ultimately suboptimal outcomes for patients. This study sets out a taxonomy 
of threats to the credibility of health economic models. The taxonomy segregates 
threats to model credibility into three broad categories (1) unequivocal errors, (2) 
violations and (3) matters of judgement, and maps these across the main elements of 
the model development process. These three categories of threats to model credibility 
are defined according to the existence of criteria for judging correctness, the degree 
of force with which such criteria can be applied, and the means by which potential 
threats can be handled. A range of suggested processes and techniques for avoid-
ing and identifying these threats is put forward with the intention of prospectively 
increasing the credibility of any given model.
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